A5011730639- Cancer Immunotherapy and Biomarkers
- Cholangiocarcinoma and Gallbladder Cancer Studies
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Glycosylation and Glycoproteins Research
- Radiopharmaceutical Chemistry and Applications
- Immunotherapy and Immune Responses
- Gastric Cancer Management and Outcomes
- Lung Cancer Treatments and Mutations
- Hepatocellular Carcinoma Treatment and Prognosis
- Gallbladder and Bile Duct Disorders
- Lung Cancer Research Studies
- SARS-CoV-2 and COVID-19 Research
- Peptidase Inhibition and Analysis
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Cancer Diagnosis and Treatment
- Head and Neck Cancer Studies
- Nausea and vomiting management
- COVID-19 and healthcare impacts
- Metastasis and carcinoma case studies
- Pathogenesis and Treatment of Hiccups
- Liver Disease Diagnosis and Treatment
- Pediatric Hepatobiliary Diseases and Treatments
- Cancer Mechanisms and Therapy
Chulalongkorn University
2016-2025
King Chulalongkorn Memorial Hospital
2013-2025
Thai Red Cross Society
2018-2025
Memorial Sloan Kettering Cancer Center
2016
University of Edinburgh
2016
The University of Texas MD Anderson Cancer Center
2010
BACKGROUND: Patients with advanced biliary tract cancer have a poor prognosis, and first-line standard of care (gemcitabine plus cisplatin) has remained unchanged for more than 10 years. The TOPAZ-1 trial evaluated durvalumab chemotherapy patients cancer. METHODS: In this double-blind, placebo-controlled, phase 3 study, we randomly assigned previously untreated unresectable or metastatic recurrent disease 1:1 to receive placebo in combination gemcitabine cisplatin up eight cycles, followed...
378 Background: BTC is a rare, heterogenous cancer with poor prognosis. Reports on immunogenic features of suggest checkpoint inhibition may result in antitumor immune responses, and limited clinical activity has been seen single agents advanced settings. Durvalumab (PD-L1 inhibitor) + GemCis showed promising phase 2 study. TOPAZ-1 (NCT03875235) the first global 3 study to evaluate first-line immunotherapy BTC. Methods: In this double-blind study, pts previously untreated for unresectable...
265 Background: Treatment options for cholangiocarcinoma (CCA) after progression on first-line gemcitabine-based therapy are limited. Fibroblast growth factor receptor 2 ( FGFR2) gene fusions occur in 13–17% of intrahepatic CCA. A single-arm, phase II study (NCT02150967) evaluated infigratinib, an ATP-competitive FGFR1–3-selective oral tyrosine kinase inhibitor, previously-treated advanced CCA with FGFR fusions/rearrangements. Methods: Adult patients advanced/metastatic ≥1 line systemic...
The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer (mCRC), published in late 2022, were adapted December according to previously established standard methodology, produce Pan-Asian (PAGA) ESMO consensus guidelines management Asian mCRC. presented this manuscript represent opinions reached by a panel experts mCRC representing oncological societies China (CSCO), Indonesia (ISHMO),...
Abstract Purpose: No standard treatment exists for platinum-refractory, recurrent/metastatic nasopharyngeal cancer (NPC). This phase II study (NCT02605967) evaluated progression-free survival (PFS) of spartalizumab, an antiprogrammed cell death protein-1 (PD-1) monoclonal antibody, versus chemotherapy, in NPC. Patients and Methods: with nonkeratinizing NPC who progressed on/after platinum-based chemotherapy were enrolled. Spartalizumab was dosed 400 mg once every 4 weeks, received per...
Abstract Purpose: HER2/neu is overexpressed in up to 30% of gastroesophageal adenocarcinomas (GEA) and linked poor prognosis. Recombinant mAbs treat HER2/neu-overexpressing cancers are effective with limitations, including resistance toxicity. Therefore, we developed a therapeutic B-cell epitope vaccine (IMU-131/HER-Vaxx) consisting three fused epitopes from the extracellular domain coupled CRM197 adjuvanted Montanide. This phase Ib study aimed evaluate optimal/safe dose leading...
BACKGROUND The combination of anti-epidermal growth factor receptor (EGFR) therapy and chemotherapy is currently a preferred first-line treatment for patients with unresectable, RAS BRAF wild-type, left-sided metastatic colorectal cancer (mCRC). Several studies have also demonstrated the benefit anti-EGFR in subsequent line settings this patient population. However, direct evidence comparing effectiveness frontline vs remains limited, leaving crucial gap guiding optimal strategies. AIM To...
607 Background: Currently, durvalumab plus gemcitabine and cisplatin is a standard of care for patients with advanced biliary tract cancer (BTC). We aimed to evaluate efficacy tolerability in real world experience Thailand where there high incidence liver-fluke related cholangiocarcinoma (CCA). Methods: This an observation study BTC participating the early access program since August 2023. Data were collected analyzed toxicity. Results: Fifty participated 14 centers across Thailand. Median...
539 Background: Durvalumab plus tremelimumab (Durva/Treme) andatezolizumab bevacizumab are preferable first-line therapy for unresectable hepatocellular carcinoma (uHCC). This study aimed to evaluate the efficacy and safety of Durva/Treme in real world setting. Methods: Fifty patients with uHCC who enrolled expanded access program (EAP) as treatment from 12 centers Thailand were included. Analysis was assessed objective response rate (ORR), survival, adverse events. We also compared data...
Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal diseases. Novel molecularly targeted therapies are urgently needed. Here, we extended our studies on role protein kinase D1 (PKD1) in PDAC cell lines. Given that Panc‐1 express moderate levels PKD1, used retroviral‐mediated gene transfer to create a derivative stably over‐expresses PKD1 (Panc‐1‐PKD1). Reciprocally, shRNA targeting Panc‐28 produce under‐expressing (Panc‐28‐shPKD1). Our results demonstrate Panc‐1‐PKD1...
Abstract Aim Cardiac dysfunction is a major limitation of anthracycline treatment in cancer patients. There are several useful serum markers other types cardiomyopathy, including N‐terminal pro‐brain‐natriuretic peptide ( NT ‐pro BNP) , troponin‐ T and creatine kinase MB isoform. We investigated the potential application these biomarkers patients receiving with anthracycline. Methods collected data from 52 female breast doxorubicin cyclophosphamide every 3 weeks for four cycles. function...
What is this summary about? This a describing the results of Phase III study called TOPAZ-1. The looked at treatment with durvalumab (a type immunotherapy) and chemotherapy to treat participants advanced biliary tract cancer (BTC). Advanced BTC usually diagnosed late stages disease, when it cannot be cured by surgery. included who had not received previous treatment, or their come back least 6 months after receiving surgery that aimed cure disease. Participants placebo chemotherapy. aim was...
Introduction: Atezolizumab plus bevacizumab is a commonly used first-line regimen for advanced hepatocellular carcinoma (HCC) treatment owing to its superior outcomes compared sorafenib. However, optimal subsequent options patients with HCC who progressed on atezolizumab remain unclear. Methods: This multinational, multi-institutional, retrospective study included from 22 centers in five Asia-Pacific countries were treated bevacizumab, which was discontinued any reason. The endpoints...
To compare incidences of hypersensitivity reaction (HSR) between original and generic taxanes including paclitaxel docetaxel.We conducted a prospective study enrolling all patients receiving at King Chulalongkorn Memorial Hospital. Taxanes were infused accordingly to the step-wise rate escalation protocol this hospital. Active surveillance for HSRs was performed. During period, there only 1 brand used each taxane. We primarily compared HSR drugs taxane.During period from January December 31,...
PURPOSE Atezolizumab plus bevacizumab treatment is a first-line therapy for unresectable hepatocellular carcinoma (HCC) worldwide. The efficacy, safety, and patient-reported outcomes (PROs) of HCC in Thailand have not yet been reported. This study aimed to evaluate the PROs atezolizumab bevacizumab. MATERIALS AND METHODS From September 2020 August 2021, 30 patients with who met inclusion criteria as were enrolled. Analysis was assessed progression-free survival, overall adverse events (AEs),...
Despite a few global regions with increased incidence, cancers of the biliary tract remain rare entity. Cholangiocarcinoma has been referred to as an ‘orphan’ cancer, given its relative infrequency in Western population.
No data regarding the efficacy of a third mRNA vaccine for solid cancer patients previously primed with heterologous CoronoVac/ChAdOx1 vaccination implemented in Thailand during shortage supply are available. Forty-four who received CoronaVac-ChAdOx1 regimen were boosted COVID vaccine, either BNT162b2 or mRNA-1273. Anti-RBD IgG was measured immediately before, two weeks after, and four after dose. The antibody response compared to 87 age- gender-matched homologous ChAdOx1/ChAdOx1 regimens....
Abstract Background: There is currently no standard treatment for patients (pts) with platinum refractory, recurrent metastatic (R/M) NPC. Spartalizumab, a humanized anti-PD-1 IgG4 mAb, blocks interaction PD-L1 and PD-L2. This the first randomized phase II study to evaluate efficacy safety of spartalizumab vs CT in Methods: open-label recruited pts non-keratinizing locally advanced R/M NPC who progressed on/after platinum-based received up 2 systemic therapies. Pts were (2:1) receive or CT,...
Limited data exists regarding the efficacy of ChAdOx1-nCoV-19 vaccine against Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) in solid cancer patients. We aimed to assess immunogenicity and impact different anticancer therapies for malignancies on immune response.This prospective, longitudinal observational study following vaccination among 385 patients active treatment was conducted two oncology centers. Participants received first dose between June 18 July 27, 2021 second at...
The study aimed to evaluate vaccine-related adverse events (VRAEs) following ChAdOx1-nCoV-19 vaccine in solid cancer patients receiving treatment compared healthy controls. 399 and 90 volunteers were enrolled. In the overall population, incidence of VRAEs was significantly lower than (57% vs 80%, P < .001). Because mean age higher (59 48 years, .001), we analyzed age-matched comparison found that there no significant difference between two groups (74% 79%, .32). Most mild severity both...